Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q4 2024 Earnings Presentation
19 slides from Angiodynamics's earnings presentation, Jul 16, 2024
Slide 1: Fourth Quarter and Full Year Earnings Presentation
AngioDynamics Fourth Quarter and Full Year Earnings Presentation July 16, 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: FY Q4 and Full Year 2024 Key Takeaways
FY Q4 and Full Year 2024 Key Takeaways Commercial and operational execution in combination with the benefits of our strategic transformation positions AngioDynamics to drive accelerated, profitable growth moving forward COMMERCIAL EXECUTION • +5.3% YoY Pro Forma FY 2024 revenue growth • Second conse
Slide 4: Q4 FY 2024 Financial Snapshot
Q4 FY 2024 Financial Snapshot Net Sales Segment Revenue Contribution $69.8 $71.1 Q4 23 Q4 24 $26.4 $29.3 +11.3% 38% 41% Pro Forma Growth 62% 59% Med Tech Med Device Med Tech Med Device $43.4 (3.8)% $41.8 Pro Forma Growth Segment Gross Margin Q4 23 Q4 24 47.4% 64.1% Med Device Med Tech Med Device Med
Slide 5: FY 2024 Financial Snapshot
FY 2024 Financial Snapshot Net Sales Segment Revenue Contribution $270.7 FY 23 FY 24 $257.2 $106.0 37% 39% $96.2 +10.1% Pro Forma Growth 61% 63% Med Tech Med Device Med Tech Med Device $161.0 $164.8 2.4% Segment Gross Margin Pro Forma Growth FY 23 FY 24 47.7% 63.3% Med Device Med Tech Med Device Med
Slide 6: 3 Year Strategic Transformation
3 Year Strategic Transformation Med Tech TAM Pursue Larger, Faster Growing Markets $10 B Significantly expanded applicability of Med Tech portfolio through $3 B +233% R&D, M&A, and clinical / regulatory initiatives Med Tech Revenue Mix FY 2021 FY 2024 39% Drive Portfolio Transformation 19% Exited an
Slide 7: Med Tech - Auryon
Med Tech - Auryon Period Sales YoY Growth Q4 2024 $13.0M 12% FY 2024 $47.1M 16% • Cumulative sales of over $130M since launch in Sept 2020 • Launched Auryon XL Radial Catheter in FY24 • CE Mark approval expected in Q1 FY25 7
Slide 8: Med Tech - Thrombus Management
Med Tech - Thrombus Management Q4 2024 Sales YoY Growth FY 2024 Sales YoY Growth AngioVac $5.9M (4%) AngioVac $23.1M (6%) AlphaVac $1.9M 7% AlphaVac $6.7M (6%) Total $7.8M (2%) Total $29.8M (6%) AlphaVac • Completed APEX-AV IDE study in Pulmonary Embolism (PE) in Q3 FY24 • Received FDA 510(k) & CE M
Slide 9: Med Tech - NanoKnife
Med Tech - NanoKnife Q4 2024 Sales YoY Growth FY 2024 Sales YoY Growth Disposables $5.4M 18% Disposables $18.0M 16% Capital $2.0M 248% Capital $6.5M 100% Total $7.4M 43% Total $24.5M 30% • Completed enrollment of PRESERVE trial in July of 2023, designed to prove that NanoKnife is a safe and effectiv
Slide 10: Med Device
Med Device Q4 2024 Sales YoY Growth FY 2024 Sales YoY Growth Core Peripheral $19.8M 2% Core Peripheral $76.4M 3% Venous / EVLT $6.4M (11%) Venous / EVLT $26.6M 4% Ports $9.4M 0% Ports $36.3M 7% Solero Microwave $4.6M (14%) Solero Microwave $19.1M (2%) Alatus and Isoloc Balloons $1.1M (6%) Alatus and
Slide 11: Key Operational Milestones
Key Operational Milestones C.R. Bard Patent Litigation Settlement • In April of 2024, the Company reached a settlement agreement with Becton, Dickinson and Company (BD) and C. R. Bard, Inc. (Bard), putting an end to a decade-long intellectual property litigation. With this resolution, the Company ca
Slide 12: Fiscal Year 2025 Guidance
Fiscal Year 2025 Guidance Metric Guidance Full Year Net Sales $282 - $288 million Med Tech Net Sales 10 – 12% YoY growth Med Device Net Sales 1 – 3% YoY growth Gross Margin 52 - 53% Adjusted EBITDA ($2.5) - $0 million Adjusted EPS ($0.38) – ($0.42) 12
Slide 13: Fiscal Year 2025 Catalysts
Fiscal Year 2025 Catalysts Auryon • Pursuing international expansion following our CE Mark • Increased penetration in the hospital setting in the U.S. AlphaVac • Full commercial launch of PE indication in U.S. and CE Marked countries • Launch new products to refine and enhance usability NanoKnife •
Slide 14: Appendix
Appendix 14
Slide 15: Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements
Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements (in thousands, except per share data) (in thousands, except per share data) 15
Slide 16: Reconciliation of GAAP to Non-GAAP Adjusted Net Loss and EPS
Reconciliation of GAAP to Non-GAAP Reconciliation of Net Loss to Adjusted Adjusted Net Loss and EPS EBITDA (in thousands, except per share data) (in thousands, except per share data) 16
Slide 17: Reconciliation of Non-GAAP Pro Forma Net Loss to Adjusted Pro Forma Net Loss
Reconciliation of Non-GAAP Pro Forma Reconciliation of Non-GAAP Pro Forma Net Loss to Adjusted Pro Forma Net Loss Net Loss to Adjusted Pro Forma EBITDA and EPS (in thousands, except per share data) (in thousands, except per share data) 17
Slide 18: Detail of Acquisition, Restructuring and Other Items, net
Detail of “Acquisition, Restructuring and Other Items, net” 18
Slide 19: Reconciliation of GAAP to Non-GAAP Pro Forma Sales and Gross Margin by Product Category
Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category (in thousands) (in thousands) 19